valine has been researched along with eplerenone in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fakouhi, K; He, W; Krause, S; Krum, H; Nolly, H; Roniker, B; Workman, D | 1 |
| Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T | 1 |
| Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M | 1 |
| Fukuda, N; Fukushima, H; Hirata, H; Ishimitsu, T; Kobayashi, E; Kobayashi, N; Koguchi, W; Machida, Y; Mamada, Y; Suzuki, N; Tabei, K; Takeshima, H; Yokotsuka, F | 1 |
| Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K | 1 |
1 trial(s) available for valine and eplerenone
| Article | Year |
|---|---|
Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients.
Topics: Abdominal Pain; Adolescent; Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzoates; Biphenyl Compounds; Blood Pressure; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Eplerenone; Female; Headache; Heart Rate; Humans; Hypertension; Irbesartan; Losartan; Male; Middle Aged; Patient Dropouts; Renin-Angiotensin System; Spironolactone; Telmisartan; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2002 |
4 other study(ies) available for valine and eplerenone
| Article | Year |
|---|---|
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan | 2006 |
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation | 2008 |
Effect of eplerenone on endothelial progenitor cells and oxidative stress in ischemic hindlimb.
Topics: Angiopoietin-1; Angiopoietin-2; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Endothelial Cells; Eplerenone; Hindlimb; Immediate-Early Proteins; Ischemia; Male; Mineralocorticoid Receptor Antagonists; Monocytes; NADPH Oxidases; Nitric Oxide Synthase Type III; Oxidative Stress; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Spironolactone; Stem Cells; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factors | 2010 |
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan | 2011 |